Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00074607 · ClinicalTrials.gov registry record · Phase 1
Intrathecal Gemcitabine to Treat Neoplastic Meningitis, IT Gemcitabine
A Phase 1 study, sponsored by Baylor College of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00074607 is a Phase 1 study that was terminated before completion, run by Baylor College of Medicine. The registered enrollment target is 10 participants.
The verdict
NCT00074607, a Phase 1 study, was terminated before completion, sponsored by Baylor College of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Subject's are being asked to take part in this study because he or she has a type of cancer that has spread to the meninges (tissues that cover the brain and spinal cord). There is no known effective treatment for this specific disease or the subject has received all of the treatments that are known to work for his or her specific disease without success. Currently, there is no other effective treatment for this type of cancer. The purposes of this study are: * to determine the highest dose of gemcitabine, an anti-cancer drug, that can safely be given directly into the spinal fluid of children and adults whose cancer no longer responds to standard treatment; * to find out what effects (good and bad) gemcitabine has when given directly into the cerebrospinal fluid (called intrathecal administration) in children and adults with neoplastic meningitis (cancer that has spread to the lining of the brain and spinal cord); * to determine if gemcitabine is beneficial to the patient; * to understand how gemcitabine is handled by the body after intrathecal administration.
Interventions
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2001-12 |
| Est. Completion | 2007-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00074607
The ClinicalTrials.gov registry entry for NCT00074607 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gemcitabine is the first listed.
NCT00074607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00074607 about?
NCT00074607 is a clinical study titled "Intrathecal Gemcitabine to Treat Neoplastic Meningitis, IT Gemcitabine". Subject's are being asked to take part in this study because he or she has a type of cancer that has spread to the meninges (tissues that cover the brain and spinal cord). There is no known effective treatment for this specific disease or the subject has received all of the treatments that are know...
What is the current status of trial NCT00074607?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2001-12. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00074607?
The interventions under investigation include: Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00074607?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.